Do analysts prefer ADXS or IFRX?

InflaRx has a consensus price target of $7.00, suggesting a potential upside of 284.62%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Is ADXS or IFRX more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A InflaRx N/A -88.30% -65.77%

Do analysts recommend ADXS or HUMA?

Humacyte has a consensus target price of $6.25, suggesting a potential upside of 852.45%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts recommend PYXS or ADXS?

Pyxis Oncology currently has a consensus price target of $6.86, indicating a potential upside of 204.76%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Pyxis Oncology is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PYXS or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Ayala Pharmaceuticals N/A N/A N/A

Do analysts rate AARD or ADXS?

Aardvark Therapeutics currently has a consensus price target of $16.30, suggesting a potential upside of 194.76%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.46 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AARD or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -61.71% -56.29% Ayala Pharmaceuticals N/A N/A N/A

Do analysts rate UNCY or ADXS?

Unicycive Therapeutics currently has a consensus target price of $21.75, indicating a potential upside of 299.08%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is UNCY or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Ayala Pharmaceuticals N/A N/A N/A

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 07/17/2026

Compare

ADXS vs. IFRX, HUMA, PYXS, AARD, and UNCY

Should you buy Ayala Pharmaceuticals stock or one of its competitors? MarketBeat compares Ayala Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ayala Pharmaceuticals include InflaRx (IFRX), Humacyte (HUMA), Pyxis Oncology (PYXS), Aardvark Therapeutics (AARD), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry.

How does Ayala Pharmaceuticals compare to InflaRx?

Ayala Pharmaceuticals (NASDAQ:ADXS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

InflaRx has a consensus price target of $7.00, suggesting a potential upside of 284.62%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ayala Pharmaceuticals' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
InflaRx	N/A	-88.30%	-65.77%

In the previous week, InflaRx had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for InflaRx and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled InflaRx'saverage media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
InflaRx	Neutral

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market.

Ayala Pharmaceuticals has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
InflaRx	$30K	4,385.59	-$51.63M	-$0.71	N/A

Summary

InflaRx beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Humacyte?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Humacyte has lower revenue, but higher earnings than Ayala Pharmaceuticals. Humacyte is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Humacyte	$2.04M	71.42	-$40.83M	-$0.57	N/A

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market.

In the previous week, Humacyte had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Humacyte and 0 mentions for Ayala Pharmaceuticals. Humacyte's average media sentiment score of 0.51 beat Ayala Pharmaceuticals' score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Humacyte	Positive

Humacyte has a consensus target price of $6.25, suggesting a potential upside of 852.45%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Ayala Pharmaceuticals has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Ayala Pharmaceuticals' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Summary

Humacyte beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Ayala Pharmaceuticals' return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Ayala Pharmaceuticals	N/A	N/A	N/A

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pyxis Oncology has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Pyxis Oncology currently has a consensus price target of $6.86, indicating a potential upside of 204.76%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Pyxis Oncology is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	10.28	-$79.62M	-$1.31	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

In the previous week, Pyxis Oncology had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 4 mentions for Pyxis Oncology and 0 mentions for Ayala Pharmaceuticals. Pyxis Oncology's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Pyxis Oncology	Neutral
Ayala Pharmaceuticals	Neutral

Summary

Pyxis Oncology beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Ayala Pharmaceuticals' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Ayala Pharmaceuticals	N/A	N/A	N/A

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aardvark Therapeutics has a beta of 3.93, meaning that its stock price is 293% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Aardvark Therapeutics currently has a consensus price target of $16.30, suggesting a potential upside of 194.76%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

In the previous week, Aardvark Therapeutics had 6 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 0 mentions for Ayala Pharmaceuticals. Aardvark Therapeutics' average media sentiment score of 0.84 beat Ayala Pharmaceuticals' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Positive
Ayala Pharmaceuticals	Neutral

Summary

Aardvark Therapeutics beats Ayala Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 0 mentions for Ayala Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.34 beat Ayala Pharmaceuticals' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Ayala Pharmaceuticals	Neutral

Unicycive Therapeutics currently has a consensus target price of $21.75, indicating a potential upside of 299.08%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Ayala Pharmaceuticals	N/A	N/A	N/A

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Unicycive Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	219.52	-$26.56M	-$2.21	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

Unicycive Therapeutics beats Ayala Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.79M	$802.20M	$6.89B	$12.28B
Dividend Yield	N/A	4.84%	2.67%	9.39%
P/E Ratio	-0.08	1.50	27.07	23.95
Price / Sales	11.05	111.87	519.31	90.33
Price / Cash	N/A	22.05	26.68	47.25
Price / Book	-0.29	8.67	10.62	6.14
Net Income	-$48.07M	-$3.14M	$3.60B	$331.74M
7 Day Performance	N/A	-2.97%	-1.26%	-1.82%
1 Month Performance	N/A	0.74%	1.07%	-1.45%
1 Year Performance	N/A	28.18%	23.63%	16.32%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
IFRX InflaRx	2.1132 of 5 stars	$1.98 -2.2%	$7.00 +254.4%	+110.6%	$142.78M	$29.33K	N/A	60	Gap Up
HUMA Humacyte	3.9927 of 5 stars	$0.65 -5.1%	$6.25 +866.0%	-71.8%	$142.31M	$2.02M	N/A	150	Gap Up
PYXS Pyxis Oncology	2.5815 of 5 stars	$2.24 -7.7%	$6.86 +205.8%	+99.1%	$142.11M	$13.86M	N/A	60	News Coverage
AARD Aardvark Therapeutics	4.1021 of 5 stars	$6.20 -7.0%	$19.70 +217.7%	-52.4%	$135.70M	N/A	N/A	18	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. IFRX, HUMA, PYXS, AARD, and UNCY

How does Ayala Pharmaceuticals compare to InflaRx?

Summary

How does Ayala Pharmaceuticals compare to Humacyte?

Summary

How does Ayala Pharmaceuticals compare to Pyxis Oncology?

Summary

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. IFRX, HUMA, PYXS, AARD, and UNCY

How does Ayala Pharmaceuticals compare to InflaRx?

Do analysts prefer ADXS or IFRX?

Do insiders & institutionals hold more shares of ADXS or IFRX?

Is ADXS or IFRX more profitable?

Does the media favor ADXS or IFRX?

Which has more volatility & risk, ADXS or IFRX?

Which has better valuation & earnings, ADXS or IFRX?

Summary

How does Ayala Pharmaceuticals compare to Humacyte?

Which has preferable earnings & valuation, ADXS or HUMA?

Do institutionals & insiders hold more shares of ADXS or HUMA?

Which has more risk and volatility, ADXS or HUMA?

Does the media favor ADXS or HUMA?

Do analysts recommend ADXS or HUMA?

Is ADXS or HUMA more profitable?

Summary

How does Ayala Pharmaceuticals compare to Pyxis Oncology?

Is PYXS or ADXS more profitable?

Do insiders and institutionals believe in PYXS or ADXS?

Which has more risk & volatility, PYXS or ADXS?

Do analysts recommend PYXS or ADXS?

Which has stronger earnings & valuation, PYXS or ADXS?

Does the media favor PYXS or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Is AARD or ADXS more profitable?

Do institutionals & insiders hold more shares of AARD or ADXS?

Which has more volatility and risk, AARD or ADXS?

Do analysts rate AARD or ADXS?

Which has preferable earnings & valuation, AARD or ADXS?

Does the media favor AARD or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Do insiders and institutionals believe in UNCY or ADXS?

Does the media refer more to UNCY or ADXS?

Do analysts rate UNCY or ADXS?

Is UNCY or ADXS more profitable?

Which has more volatility and risk, UNCY or ADXS?

Which has preferable valuation & earnings, UNCY or ADXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools